#United States #San Francisco #BioMarin #VOXZOGO #achondroplasia

BioMarin Previews Groundbreaking Data from 2026 PES Meeting

Recently, BioMarin Pharmaceutical Inc. shared important insights from studies involving VOXZOGO® (vosoritide), a treatment specifically targeting achondroplasia in children. Set to be highlighted at the Pediatric Endocrine Society's 2026 Annual Meeting in San Francisco, this promising data showcases the long-term positive effects VOXZOGO has on health metrics beyond growth.

VOXZOGO's Impact on Growth and Health Indicators

The findings, derived from various ongoing long-term extension clinical trials, reveal remarkable advancements in several health markers for children undergoing treatment with VOXZOGO. Notably, the key measures involved arm span and bone health, which are crucial for overall development.

Improvements in Arm Span and Growth Metrics

Research indicates that the arm span Z-scores improved significantly across all age groups participating in the studies, alongside consistent arm span-to-height ratios maintained over time, crucial for ensuring proportional skeletal growth. Additionally, children who began their treatment with VOXZOGO after the age of 5 presented a notable average height increase—10.60 cm after six years and 13.59 cm after eight years—when compared to untreated cohorts, exhibiting substantial growth over time (p<0.0001).

Bradley Miller, M.D., Ph.D., a pediatric endocrinologist at the University of Minnesota Medical School, commented on the unmatched depth of evidence supporting VOXZOGO, emphasizing that such extensive data provides confidence for early intervention in ongoing treatments for children with achondroplasia.

Bone Mineral Content and Density Studies

Beyond growth metrics, a different study involving 119 children revealed VOXZOGO's significant positive influence on bone health. Measurements of bone mineral content and density, monitored through annual DXA assessments, showed a steady increase in BMC over time, while BMD Z-scores remained consistent. This finding underscores the treatment's ability to maintain bone health across lengthy treatment periods.

Exploring Hypochondroplasia and Upcoming Releases

In addition to findings regarding achondroplasia, BioMarin is also advancing research into hypochondroplasia, presenting data that illustrates VOXZOGO's effectiveness in this area. One particular study from Children's National Hospital demonstrated a significant enhancement in total body minus head bone mineral density (BMD) and bone mineral content after a year of treatment.

BioMarin is set to communicate topline results from a pivotal Phase 3 clinical trial in children suffering from hypochondroplasia during the first half of 2026. Positive data will lead to regulatory submissions seeking additional approval for this indication, which could further expand VOXZOGO’s impact.

Poster Presentations at the PES Annual Meeting

Several key research presentations will take place at the PES Annual Meeting regarding both achondroplasia and hypochondroplasia:

• - Double-Blind Study of Vosoritide in Young Children with Hypochondroplasia
• - Effect on Bone Density and Mineral Content in Pediatric Achondroplasia Patients
• - Real-World Outcomes of Vosoritide Treatment in Japan
• - Linear Growth Improvements in Hypochondroplasia

These presentations aim to furnish health professionals with evidence-based insights into the ongoing effectiveness and safety of VOXZOGO.

Understanding Achondroplasia

Achondroplasia, known as the most prevalent form of skeletal dysplasia, affects individuals' heights and can lead to other bone structure challenges. Occurring due to changes in the FGFR3 gene responsible for bone growth, it often arises from spontaneous mutations. VOXZOGO is notably directed at patients whose growth plates remain open, primarily children under the age of 18.

VOXZOGO, which acts as a significant regulator of endochondral bone growth, was first approved in 2021 and has since assisted thousands of children across over 50 countries. Continuing studies focus on vital health markers including growth and overall quality of life for the affected population.

VOXZOGO's Safety Considerations

While VOXZOGO presents promising benefits, it is essential for caregivers and patients to be informed regarding potential side effects. Some common side effects include injection site reactions, changes in blood pressure, and digestive issues. A thorough conversation with healthcare providers prior to commencing treatment will aid in maximizing the treatment's benefits while managing any risks effectively.

Conclusion

In summary, BioMarin's presentation at the Pediatric Endocrine Society's 2026 Annual Meeting promises to deliver pivotal data on VOXZOGO's effectiveness for children grappling with achondroplasia and hypochondroplasia. As the company continues to lead in research and development for rare genetic conditions, the advancement of VOXZOGO stands as a testament to ongoing improvements in the lives of children worldwide.